The Global Insulin Sensitizers Market Size is valued at USD 14.27 billion in 2022 and is predicted to reach USD 23.35 billion by the year 2031 at a 5.8% CAGR during the forecast period for 2023-2031.
Thiazolidinediones (TZDs) are referred to as "insulin sensitizers" and are also euglycemics, which normalize blood sugar. Type 2 diabetes mellitus (T2DM) has insulin sensitizers as its accepted underlying cause. Due to the restricted prescription or removal from the market of several licenced insulin sensitizers, such as thiazolidinediones (TZDs), due to safety concerns, there is now an unmet demand for safe and effective insulin sensitizers. Therefore, diabetic patients will greatly benefit from effective insulin sensitizers devoid of TZD-like adverse effects.
The World Health Organisation predicts that the morbidity of diabetes mellitus (DM), a noninfectious pandemic disease that affects the entire world, will continue to climb in the ensuing decades, which is anticipated to drive market growth. The rise in insulin sensitizers in the general population, which is the pervasive occurrence of obesity and metabolic syndrome, is responsible for the rise in type 2 diabetes (T2DM), which affects more than 90% of diabetic patients, which is another characteristic propelling the market growth during the forecast period.
Insulin sensitizers are a pathological condition where the target cells in the liver, skeletal muscle, and adipose tissue fail to respond to insulin adequately, impairing their ability to absorb and metabolize glucose effectively.
The insulin sensitizers market is segmented on the basis of the type of insulin sensitizers, indication, and distribution channel. Based on the type of insulin sensitizers, the market is segmented as thiazolidinediones (TZDs), biguanides, incretin-based indication, and others. By indication, the market is segmented into type 2 diabetes, prediabetes, and polycystic ovary syndrome (PCOS). On the basis of distribution channels includes hospital pharmacies, retail pharmacies, and online pharmacies.
The thiazolidinediones (TZDs) category is expected to hold a major share of the global insulin sensitizers market in 2022. This is attributed to Thiazolidinediones (TZDs) helping to lower blood sugar by improving muscle, fat, and liver sensitivity to insulin. TZDs are referred to as "insulin sensitizers" and "euglycemics," which are medications that help bring blood sugar levels back into the normal range without increasing the danger of low blood sugar.
The type 2 diabetes category is projected to develop at a fast rate in the global insulin sensitizers market. Type 2 diabetes mellitus is a disorder that is becoming more common and is linked to numerous metabolic abnormalities. The most noticeable characteristic of type 2 diabetes and the related metabolic problems is insulin resistance. Insulin sensitizers have numerous positive effects on lipid metabolism and atherosclerotic vascular processes, in addition to their therapeutic effects on glycemic management, which is expected to drive market development during the forecast period.
The North America insulin sensitizers market is expected to show the highest market share in terms of revenue in the near future. Increasing clinical trials on insulin sensitizers in the region are anticipated to push the market growth. Furthermore, rising research and development for various insulin sensitizers boosts the market growth. Major Market players are focusing on competition in the market, which is one of the factors propelling the market development during the forecast period.
| Report Attribute | Specifications |
| Market size value in 2022 | USD 14.27 Bn |
| Revenue forecast in 2031 | USD 23.35 Bn |
| Growth rate CAGR | CAGR of 5.8 % from 2023 to 2031 |
| Quantitative units | Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
| Historic Year | 2019 to 2022 |
| Forecast Year | 2023-2031 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments covered | By Type Of Insulin Sensitizers, Indication, And Distribution Channel |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Eli Lilly and Company, Novo Nordisk, Sanofi, Merck & Co., Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Takeda Pharmaceutical. |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Insulin Sensitizers Market By Type of Insulin Sensitizers-
Insulin Sensitizers Market By Indication-
Insulin Sensitizers Market By Distribution channel-
Insulin Sensitizers Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.